-
Innovation Ranking
Innovation Ranking – Astellas Pharma Inc
Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes...
-
Product Insights
NewNet Present Value Model: Astellas Pharma Inc’s Claudiximab
Empower your strategies with our Net Present Value Model: Astellas Pharma Inc's Claudiximab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Astellas Pharma Inc’s Bocidelpar Sulfate
Empower your strategies with our Net Present Value Model: Astellas Pharma Inc's Bocidelpar Sulfate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eiger BioPharmaceuticals Inc’s Avexitide acetate
Empower your strategies with our Net Present Value Model: Eiger BioPharmaceuticals Inc's Avexitide acetate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-4396 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-4396 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-4396 in Solid Tumor Drug Details: ASP-4396 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07799544 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07799544 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07799544 in Metastatic Melanoma Drug Details: PF-07799544 (ARRY-134) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zocaglusagene Nuzaparvovec in Pompe Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zocaglusagene Nuzaparvovec in Pompe Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zocaglusagene Nuzaparvovec in Pompe Disease Drug Details: Zocaglusagene nuzaparvovec (AT-845)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramosetron in Fecal Incontinence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramosetron in Fecal Incontinence report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramosetron in Fecal Incontinence Drug Details: Ramosetron (Nasea, Irribow) is an...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for...